Edition:
India

John Miller

Drugs standards group nixes plan to kick pharma's crab blood habit

31 May 2020

ZURICH Horseshoe crabs' icy-blue blood will remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups.

Drugs standards group nixes plan to kick pharma's crab blood habit

30 May 2020

ZURICH, May 30 Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups.

Novartis to make U.S. researchers' COVID-19 gene therapy vaccine hopeful

28 May 2020

ZURICH Novartis re-entered vaccine making on Thursday, inking a manufacturing deal with a U.S. team whose COVID-19 candidate relies on technology similar to that of the Swiss drugmaker's $2.1 million-per-patient gene therapy, Zolgensma.

Roche, Novartis highlight intensifying rivalry in eye disease, MS

27 May 2020

ZURICH Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing on Wednesday new data on drugs aimed at capturing market share from each other.

WHO expects hydroxychloroquine safety findings by mid-June

27 May 2020

ZURICH The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probably by mid-June, after safety concerns prompted the group to suspend the malaria drug's use in a large trial on COVID-19 patients.

Disruption to global immunization system could delay COVID-19 vaccinations

24 May 2020

GENEVA/ZURICH Massive disruptions to global immunisation programmes from the COVID-19 pandemic have health experts fearful that much of the developing world will not be able to get a vaccine for the new coronavirus, even once one is ready.

Disruption to global immunization system could delay COVID-19 vaccinations

23 May 2020

By Stephanie Nebehay and John Miller GENEVA/ZURICH Massive disruptions to global immunization programs from the COVID-19 pandemic have health experts fearful that much of the developing world will not be able to get a vaccine for the new coronavirus, even once one is ready.

Switzerland's Sunrise, French-owned Salt link up in $3.1 billion broadband JV

19 May 2020

ZURICH Sunrise Communications Group and French billionaire Xavier Niel's Salt Mobile launched a broadband joint venture on Tuesday targeting 1.5 million Swiss households, a new challenge to the country's largest telecoms provider, Swisscom's.

World News